Full Press Release Details
Lexaria Bioscience Receives U.S. Patent Award for its
DehydraTECHTM Delivery of THC, NSAIDs, Nicotine and
Kelowna, British Columbia December 13, 2017 Lexaria
Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the Company or Lexaria ) a drug
delivery platform innovator, announces the United States Patent and Trademark
Office ( USPTO ) has granted patent number 9,839,612 B2 for the use of
DehydraTECHTM technology as a delivery platform for a wide variety of
Active Pharmaceutical Ingredients ( APIs ) including all cannabinoids including
THC; fat soluble vitamins; non-steroidal anti-inflammatory pain medications
( NSAIDs ); and nicotine.
This granted patent completes the patent allowance process that
was announced on October 31, 2017, and this patent grant is now final. The title
of the granted patent is Food and Beverage Compositions Infused With Lipophilic
Active Agents and Methods of Use Thereof . This issued patent protects Lexaria s
intellectual property ( IP ) for the DehydraTECHTM delivery of all
the active substances noted via nearly any kind of processed food or beverage as
well as capsules and pills.
In one aspect a method of treating a condition is provided
wherein a cannabinoid is used to treat conditions selected from the group
consisting of cardiac diseases such as heart disease, ischemic infarcts, and
cardiometabolic disorders, neurological diseases such as Alzheimer s disease,
Parkinson s disease, schizophrenia, and Human Immunodeficiency Virus (HIV)
dementia; obesity; metabolic disorders such as insulin related deficiencies and
lipid profiles, hepatic diseases, diabetes, and appetite disorders; cancer
chemotherapy, benign prostatic hypertrophy; irritable bowel syndrome, biliary
diseases; ovarian disorders; marijuana abuse; and alcohol, opioid, nicotine or
Lexaria also continues to advance all of its additional patent
applications in various countries as it levers patent success in the USA. For
example, some of the Company s patent applications have recently entered the
active patent investigation phase in China, the European Union, and in Canada.
Lexaria has now locked-up the IP for its next-generation drug
delivery system said Chief Executive Officer Chris Bunka. This
ground-breaking, patented IP builds a foundation for new business opportunities
in 2018 including what could be the world s first nicotine edibles for the
smokeless tobacco industry, or improved new products for NSAID-derived pain
management, as well as in the rapidly growing cannabis market.
Lexaria s patented DehydraTECH technology is focused on
improved delivery methodologies of many commonly used API substances. As
such, it provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of
third parties. Both patented and generic API substances can utilize Lexaria s
patented technology. Lexaria s long term strategy is to partner with the world s
leading firms as they deliver best-of-class products to their existing large
Lexaria is presently investigating and will continue to pursue
additional technologies that could deliver value to its growing portfolio of
patented technologies.
Lexaria Bioscience Corp. has developed
and out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic
active molecules. Lexaria has multiple patents pending in over 40 countries
around the world and has patents granted in the USA and in Australia for
utilization of its DehydraTECHTM delivery technology. Lexaria s
technology provides increases in intestinal absorption rates; more rapid
delivery to the bloodstream; and important taste-masking benefits, for orally
administered bioactive molecules including cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp) and on Facebook
FOR FURTHER INFORMATION PLEASE CONTACT:
Alex Blanchard, Communications Manager
NetworkNewsWire (NNW)
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to: that
any additional patent protection will be realized or that patent achievements
will deliver material results. Such forward-looking statements are estimates
reflecting the Company's best judgment based upon current information and
involve a number of risks and uncertainties, and there can be no assurance that
other factors will not affect the accuracy of such forward-looking statements.
Factors which could cause actual results to differ materially from those
estimated by the Company include, but are not limited to, government regulation,
managing and maintaining growth, the effect of adverse publicity, litigation,
competition, scientific discovery, the patent application and approval process
and other factors which may be identified from time to time in the Company's
public announcements and filings. There is no assurance that existing capital is
sufficient for the Company's needs or that it will be able to raise additional
capital. There is no assurance the Company will be capable of developing,
marketing, licensing, or selling edible products containing nicotine or any
other active ingredient. There is no assurance that any planned corporate
activity, scientific research or study, business venture, technology licensing
pursuit, patent application or allowance, consumer study, or any initiative will
be pursued, or if pursued, will be successful. There is no assurance that any of
Lexaria s postulated uses, benefits, or advantages for the patented and
patent-pending technology will in fact be realized in any manner or in any part.
No statement herein has been evaluated by the Food and Drug Administration
(FDA). Lexaria-associated products are not intended to diagnose, treat, cure or
prevent any disease.
The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release.